Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578 is registered in ClinicalTrials.gov with Johnson & Johnson Enterprise Innovation Inc. as lead sponsor.

NCT NCT06311578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06311578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 10, 2024
Completion date
February 14, 2033
Enrollment
126 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms